Jennifer Facteau-Rabideau
Adult Health · Plattsburgh, NYNPI 1437406477
Payments from drug & device makers
Across 528 payments — averaging $18.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Novo Nordisk$1K
- AstraZeneca$1K
- GSK$811
- Lilly USA, LLC$661
- Amgen$427
- plus $4K from 35 others
What the payments were for
- Food & beverage$9,57799%
- Education$1371%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
How this compares
$9,713 in reported general payments places this provider in the 95th percentile of 3,828 adult health providers in New York.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 66 | $95,746 |
| OzempicSemaglutide | 39 | $75,227 |
| MounjaroTirzepatide | 61 | $73,139 |
| FarxigaDapagliflozin Propanediol | 50 | $71,425 |
| EliquisApixaban | 41 | $63,435 |
| TrulicityDulaglutide | 28 | $47,380 |
| MyrbetriqMirabegron | 43 | $40,148 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 34 | $35,622 |
| UbrelvyUbrogepant | 19 | $33,376 |
| JardianceEmpagliflozin | 14 | $21,113 |
| NucyntaTapentadol Hcl | 11 | $20,788 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 25 | $16,422 |
| Tresiba Flextouch U-100Insulin Degludec | 20 | $14,084 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 24 | $12,839 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 156 | $7,190 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $661 | $120,51989 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $1,288 | $113,469107 claims |
| GSKTrelegy Ellipta, Anoro Ellipta | $811 | $112,16891 claims |
| Novo NordiskOzempic | $1,357 | $75,22739 claims |
| PfizerEliquis | $419 | $63,43541 claims |
| Astellas Pharma US IncMyrbetriq | $228 | $40,14843 claims |
| AbbVieUbrelvy | $1,654 | $33,37619 claims |
| Boehringer IngelheimJardiance | $381 | $21,11314 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,828 adult health providers in New York.
Other adult health in Plattsburgh
- Jodi HamelPlattsburgh$17K
- Marguerite CallahanNew York$1.4M
- Donna CatameroNew York$279K
- Kristen DurkinPort Jefferson Station$255K
- Katelyn McCormackAmherst$201K
- Mary CiechoskiBuffalo$200K
- Patricia LorussoLancaster$161K
- Jennifer FioriniGlens Falls$151K
- Tia AlbroRochester$142K
- Maria Gigante-BaggettEast Syracuse$92K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.